Abstract: PO0976
Changes in Cardiac Microvascular Function in Persons with Type 2 Diabetes in Relation to Kidney Function
Session Information
- Diabetic Kidney Disease: Clinical - 1
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 602 Diabetic Kidney Disease: Clinical
Authors
- Rasmussen, Ida, Steno Diabetes Center Copenhagen, Gentofte, Denmark
- Hasbak, Philip, Rigshospitalet, Kobenhavn, Denmark
- Von Scholten, Bernt Johan, Steno Diabetes Center Copenhagen, Gentofte, Denmark
- Laursen, Jens christian, Steno Diabetes Center Copenhagen, Gentofte, Denmark
- Hein Zobel, Emilie, Steno Diabetes Center Copenhagen, Gentofte, Denmark
- Holmvang, Lene, Rigshospitalet, Kobenhavn, Denmark
- Ripa, Rasmus S., Rigshospitalet, Kobenhavn, Denmark
- Rossing, Peter, Steno Diabetes Center Copenhagen, Gentofte, Denmark
- Kjaer, Andreas, Rigshospitalet, Kobenhavn, Denmark
- Hansen, Tine, Steno Diabetes Center Copenhagen, Gentofte, Denmark
Background
The myocardial flow reserve (MFR) reflects the function of both large epicardial arteries and the microcirculation. Coronary artery calcium score (CACS) is a measure of coronary atherosclerosis. Cardiac 82Rb PET/CT provides a measurement of both MFR and CACS. Knowledge on changes in MFR and CACS over time and the impact of kidney function on these changes is lacking
Methods
In 2013 we recruited 60 persons with type 2 diabetes (T2D) and 30 non-diabetic controls (C); all free of overt cardiovascular disease. All underwent a cardiac 82Rb PET/CT scan. In 2019, survivors (n=82) were invited for a repeated cardiac 82Rb PET/CT after a similar protocol. 29 with T2D and 19 C participated.
Results
Median [interquartile range] duration between visits was 6.2 [6.0–6.3] years. The Table summarizes kidney function, MFR and CACS at the 2 visits. MFR was lower in persons with T2D compared to C but change in MFR was similar between groups (p=0.62) and did not differ between visits within the groups (C:p=0.51, T2D:p=0.08). CACS was higher in persons with T2D compared to C at both visits. CACS increased between visits within both groups (C:p=0.015, T2D:p<0.001), and the change was higher in T2D (p=0.002).
In the total cohort, lower eGFR at baseline was associated with higher decline in MFR (p=0.027), but not after adjustment (p=0.70). Increase in CACS was higher in men (p=0.03), but not after adjustment (p=0.07). Changes in MFR and CACS were not associated with other risk factors at baseline.
Conclusion
MFR was lower in T2D compared to C but did not change significantly in either of the groups when evaluated over 6 years. Kidney function had no independent impact on changes in MFR or CACS
Type 2 diabetes (n=29) | Controls (n=19) | P (unadjusted) | P (adjusted) | |
UAER visit 1 (mg/24-h) | 27.3 [6.5, 145] | 5.5 [5.0, 6.5] | <0.001 | |
eGFR visit 1 (ml/min/1.73m2) | 81.1 (21.5) | 87.6 (11.1) | 0.23 | |
MFR visit 1 | 2.6 (0.7) | 3.3 (0.7) | 0.001 | 0.83 |
MFR visit 2 | 2.4 (0.6) | 3.2 (0.9) | <0.001 | 0.46 |
MFR difference | -0.27 [-0.48, 0.06] | -0.20 [-0.65, 0.50] | 0.62 | 0.32 |
CACS visit 1 | 180 [22, 275] | 0 [0, 54] | <0.001 | 0.03 |
CACS visit 2 | 560 [136, 981] | 18 [0, 116] | <0.001 | 0.04 |
CACS difference | 301 [72, 830] | 9 [0, 62] | 0.002 | 0.12 |
Adjustment included; age, sex, BMI, eGFR, urinary albumin excretion rate, 24-h systolic BP, heart rate, total cholesterol and smoking